WHO Raises Concern Over Acute Shortage of Weight-Loss Jabs
Less than a tenth of people who could benefit from weight-loss injections such as Wegovy are able to get them, states the global health agency as it releases its inaugural recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for broader and more equitable access to GLP-1 medication.
Per projections, more than two billion are projected to be obese by 2030 without intervention.
"The latest guidance affirms that excess weight is a chronic disease that can be managed with holistic and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant obstacles to universal access to the injections that can assist patients in reducing substantial body mass, notes the body.
GLP-1 Therapy Supply Crisis
Even in the current most optimistic scenario, the supply of GLP-1 therapies would only suffice for approximately 100 million people – less than 10% of the global need, as stated by the WHO.
The advice encourages governments and firms to expand access, by strategies including licensing agreements.
The intellectual property rights on the active ingredient – the core component of a leading brand – is set to lapse in a number of countries in 2026.
The Way Obesity Jabs Function
GLP-1 drugs imitate a body's own hormone to delay gastric emptying, reduce hunger and enhance satiety so individuals reduce food intake.
Patients usually begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Studies suggests people may see weight return a year later of stopping the drug, because their typical appetite return.
Being carrying excess weight raises your risk for experiencing diseases, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight concerns individuals in all nations and was responsible for millions of deaths worldwide in 2024, as per the health agency.